Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Large Increase in Short Interest

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 5,610,000 shares, an increase of 26.6% from the February 29th total of 4,430,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is presently 5.1 days.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Wolfe Research started coverage on shares of Alpine Immune Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $44.00 price objective for the company. Morgan Stanley increased their target price on shares of Alpine Immune Sciences from $30.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. HC Wainwright boosted their price target on shares of Alpine Immune Sciences from $32.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $44.00 price objective (up previously from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Alpine Immune Sciences presently has a consensus rating of “Buy” and a consensus price target of $38.86.

Read Our Latest Report on ALPN

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Walleye Capital LLC increased its position in Alpine Immune Sciences by 13.1% during the third quarter. Walleye Capital LLC now owns 186,273 shares of the biotechnology company’s stock worth $2,133,000 after buying an additional 21,600 shares in the last quarter. Nan Fung Group Holdings Ltd purchased a new stake in Alpine Immune Sciences during the 3rd quarter worth about $2,087,000. Schonfeld Strategic Advisors LLC increased its position in Alpine Immune Sciences by 604.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 90,937 shares of the biotechnology company’s stock worth $1,041,000 after purchasing an additional 78,037 shares in the last quarter. Decheng Capital Management III Cayman LLC acquired a new position in Alpine Immune Sciences in the 3rd quarter valued at about $76,810,000. Finally, Swiss National Bank purchased a new position in Alpine Immune Sciences in the 3rd quarter valued at about $483,000. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Price Performance

Shares of NASDAQ ALPN opened at $39.64 on Friday. The firm’s 50-day moving average is $32.37 and its two-hundred day moving average is $20.73. The company has a market capitalization of $2.60 billion, a PE ratio of -61.94 and a beta of 1.13. Alpine Immune Sciences has a 12-month low of $6.71 and a 12-month high of $42.88.

Alpine Immune Sciences Company Profile

(Get Free Report)

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Read More

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.